Abstract The introduction of therapeutics targeting specific tumor-promoting oncogenic or non-oncogenic signaling pathways has revolutionized cancer treatment. Mechanistic (previously mammalian) target of rapamycin (mTOR), a highly conserved Ser/Thr kinase, is a central hub of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR network, one of the most frequently deregulated signaling pathways in cancer, that makes it an attractive target for therapy. Numerous mTOR inhibitors have progressed to clinical trials and two of them have been officially approved as anticancer therapeutics. However, mTOR-targeting drugs have met with a very limited success in cancer patients. Frequently, the primary impediment to a successful targeted therapy in cancer is drug-resistance, either from the very beginning of the therapy (innate resistance) or after an initial response and upon repeated drug treatment (evasive or acquired resistance). Drug-resistance leads to treatment failure and relapse/progression of the disease. Resistance to mTOR inhibitors depends, among other reasons, on activation/deactivation of several signaling pathways, included those regulated by glycogen synthase kinase-3 (GSK3), a protein that targets a vast number of substrates in its repertoire, thereby orchestrating many processes that include cell proliferation and survival, metabolism, differentiation, and stemness. A detailed knowledge of the rewiring of signaling pathways triggered by exposure to mTOR inhibitors is critical to our understanding of the consequences such perturbations cause in tumors, including the emergence of drug-resistant cells. Here, we provide the reader with an updated overview of intricate circuitries that connect mTOR and GSK3 and we relate them to the efficacy (or lack of efficacy) of mTOR inhibitors in cancer cells.
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer / Evangelisti, C; Chiarini, F; Paganelli, F; Marmiroli, S; Martelli, Am. - In: BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH. - ISSN 0167-4889. - 1867:4(2020), pp. 1-10.
|Data di pubblicazione:||2020|
|Data di prima pubblicazione:||26-dic-2019|
|Titolo:||Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer|
|Autore/i:||Evangelisti, C; Chiarini, F; Paganelli, F; Marmiroli, S; Martelli, Am|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.bbamcr.2019.118635|
|Codice identificativo ISI:||WOS:000515431200015|
|Codice identificativo Scopus:||2-s2.0-85078117886|
|Codice identificativo Pubmed:||31884070|
|Citazione:||Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer / Evangelisti, C; Chiarini, F; Paganelli, F; Marmiroli, S; Martelli, Am. - In: BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH. - ISSN 0167-4889. - 1867:4(2020), pp. 1-10.|
|Tipologia||Articolo su rivista|
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris